A phase 1 open-label trial shows that smad7 antisense oligonucleotide (GED0301) does not increase the risk of small bowel strictures in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 9, 2012, Pages 850-857

  Zorzi, F ^a   Calabrese, E ^a   Monteleone, I ^a   Fantini, M ^a   Onali, S ^a   Biancone, L ^a   Pallone, F ^a   Monteleone, G ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHITINASE; FIBROBLAST GROWTH FACTOR 2; GED0301; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INTESTINE RESECTION; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; RELAPSE; SMALL INTESTINE;

ADULT; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTESTINAL OBSTRUCTION; INTESTINE, SMALL; MALE; MATRIX METALLOPROTEINASES; OLIGONUCLEOTIDES, ANTISENSE; PROSPECTIVE STUDIES; RISK FACTORS; SMAD7 PROTEIN; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSFORMING GROWTH FACTOR BETA1; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878568056     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12051     Document Type: Article

References (34)

1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol 2010; 28: 573-621.
2. Strober W, Fuss I, Mannon P. The fundamental basis of inflammatory bowel disease. J Clin Invest 2007; 117: 514-21. (Pubitemid 46348505)
3. Wahl SM. Transforming growth factor beta: the good, the bad, and the ugly. J Exp Med 1994; 180: 1587-90. (Pubitemid 24328550)
4. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998; 16: 137-61.
5. Monteleone G, Kumberova A, Croft NM, Mc Kenzie C, Steer HW, Mac Donald TT. Blocking Smad7 restores TGF-beta1 signaling in chronic inflammatory bowel disease. J Clin Invest 2001; 108: 601-9. (Pubitemid 32777740)
6. Monteleone G, Boirivant M, Pallone F, Mac Donald TT. TGF-beta1 and Smad7 in the regulation of IBD. Mucosal Immunol 2008; 1(Suppl. 1): S50-3.
7. Boirivant M, Pallone F, Di Giacinto C, et al. Inhibition of Smad7 with a specific antisense oligonucleotide facilitates TGF-beta1-mediated suppression of colitis. Gastroenterology 2006; 131: 1786-98. (Pubitemid 44958514)
8. Monteleone G, Fantini MC, Onali S, et al. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol Ther 2012; 20: 870-6.
9. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50. (Pubitemid 34784976)
10. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol 2007; 102: 439-48. (Pubitemid 46160558)
11. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-92. (Pubitemid 24333194)
12. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor beta signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009; 58: 777-89.
13. Van Assche G, Dignass A, Panes J, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis 2010; 4: 7-27.
14. Calabrese E, La Seta F, Buccellato A, et al. Crohn's disease: a comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema. Inflamm Bowel Dis 2005; 11: 139-45. (Pubitemid 40711218)
15. Parente F, Greco S, Molteni M, et al. Oral contrast enhanced bowel ultrasonography in the assessment of small intestine Crohn's disease. A prospective comparison with conventional ultrasound, X-ray studies, and ileocolonoscopy. Gut 2004; 53: 1652-7. (Pubitemid 39434111)
16. Pallotta N, Tomei E, Viscido A, et al. Small intestine contrast ultrasonography: an alternative to radiology in the assessment of small bowel disease. Inflamm Bowel Dis 2005; 11: 146-53. (Pubitemid 40711219)
17. Calabrese E, Zorzi F, Pallone F. Ultrasound of the small bowel in Crohn's disease. Int J Inflam 2012; 2012: 964720.
18. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signalling pathways. Biochem J 2002; 365: 119-26. (Pubitemid 34756146)
19. Vind I, Johansen JS, Price PA, Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003; 38: 599-605. (Pubitemid 36724038)
20. Koutroubakis IE, Petinaki E, Dimoulios P, et al. Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int J Colorectal Dis 2003; 18: 254-9. (Pubitemid 36764173)
21. Di Sabatino A, Ciccocioppo R, Armellini E, et al. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm Bowel Dis 2004; 10: 573-7. (Pubitemid 39276464)
22. Pender SL, MacDonald TT. Matrix metalloproteinases and the gut-new roles for old enzymes. Curr Opin Pharmacol 2004; 4: 546-50. (Pubitemid 40267866)
23. McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003; 162: 1355-60. (Pubitemid 36350679)
24. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 2007; 39: 733-9. (Pubitemid 47053808)
25. Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 241-6. (Pubitemid 30304217)
26. Gao Q, Meijer MJ, Schluter UG, et al. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 2007; 13: 693-702. (Pubitemid 46909983)
27. Pallotta N, Vincoli G, Montesani C, et al. Small intestine contrast ultrasonography (SICUS) for the detection of small bowel complications in crohn's disease: a prospective comparative study versus intraoperative findings. Inflamm Bowel Dis 2012; 18: 74-84.
28. Panés J, Bouzas R, Chaparro M, Fry DH, Pollok RC. Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complication of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 125-45.
29. Chatu S, Pilcher J, Saxena SK, Fry BH, Pollok RC. Diagnostic accuracy of small intestine ultrasonography using an oral contrast agent in Crohn's disease: comparative study from the UK. Clin Radiol 2012; 67: 553-9.
30. Monteleone G, Pallone F, MacDonald TT. Smad7 in TGF-beta-mediated negative regulation of gut inflammation. Trends Immunol 2004; 25: 513-7. (Pubitemid 39208348)
31. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8. (Pubitemid 30408720)
32. Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004; 18: 816-27.
33. Di Sabatino A, Pender SL, Jackson CL, et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-49. (Pubitemid 47031137)
34. Lawrance IC, Wu F, Leite AZ, et al. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-kappa B. Gastroenterology 2003; 125: 1750-61. (Pubitemid 37500440)